Calcifediol-13C5 (monohydrate)

• UNSPSC Description:

  Calcifediol-13C5 monohydrate is the 13C-labeled Calcifediol monohydrate. Calcifediol monohydrate (25-hydroxy Vitamin D3 monohydrate), is an effective VDR ligand and VD supplement. Calcifediol is a prohormone of the vitamin D endocrine system (VDES) and is hydroxylated in the liver to produce the active form, calcitriol. Calcifediol can rapidly increase serum VD levels[1][2][3].

• Target Antigen:

  Endogenous Metabolite; Isotope-Labeled Compounds; VD/VDR

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Metabolic Enzyme/Protease;Others;Vitamin D Related/Nuclear Receptor

• Field of Research:

  Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/calcifediol-13c5-monohydrate.html

• Solubility:

  10 mM in DMSO

• Smiles:

  C=C1CC[C@H](O)C/C1=C/C=C2[C@]3([C@@](C)([C@H](CC3)[C@@H](C[13CH2][13CH2][13C]([13CH3])(O)[13CH3])C)CCC/2)[H].O

• Molecular Weight:

  423.62

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Castoldi A, et al. Calcifediol-loaded liposomes for local treatment of pulmonary bacterial infections. Eur J Pharm Biopharm. 2016 Nov 22.|[3]Wei Zheng, et al. Vitamin D-induced vitamin D receptor expression induces tamoxifen sensitivity in MCF-7 stem cells via suppression of Wnt/β-catenin signaling. Biosci Rep. 2018 Dec 7;38(6):BSR20180595.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported